Serum Glycan Markers for Evaluation of Disease Activity and Prediction of Clinical Course in Patients with Ulcerative Colitis

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Miyahara, Koji ^a   Nouso, Kazuhiro ^a   Saito, Shunsuke ^a   Hiraoka, Sakiko ^a   Harada, Keita ^a   Takahashi, Sakuma ^a   Morimoto, Yuki ^a   Kobayashi, Sayo ^a   Ikeda, Fusao ^a   Miyake, Yasuhiro ^a   Shiraha, Hidenori ^a   Takaki, Akinobu ^a   Okada, Hiroyuki ^a,b   Amano, Maho ^c,d   Hirose, Kazuko ^c   Nishimura, Shin Ichiro ^c,d   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d Hokkaido University and Medicinal Chemistry Pharmaceuticals LLC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINOSALICYLIC ACID; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN; GLYCAN; MERCAPTOPURINE;

ADULT; ALBUMIN BLOOD LEVEL; APHERESIS; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIET THERAPY; DISEASE ACTIVITY; FEMALE; GLYCOBIOLOGY; HUMAN; LEUKOCYTAPHERESIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROCTOCOLECTOMY; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SWEETBLOT; THROMBOCYTE COUNT; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYSACCHARIDES; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84885072798     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074861     Document Type: Article

References (31)

1. Baumgart DC, Sandborn WJ, (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369: 1641-1657.
2. Vermeire S, Van Assche G, Rutgeerts P, (2006) Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 55: 426-431.
3. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, et al. (2011) Guidelines for the management of inflammatory bowel disease in adults. Gut 60: 571-607.
4. Simpson P, Papadakis KA, (2008) Endoscopic evaluation of patients with inflammatory bowel disease. Inflamm Bowel Dis 14: 1287-1297.
5. Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, et al. (2008) C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 57: 1518-1523.
6. Vilela EG, Torres HO, Martins FP, Ferrari M.L, Andrade MM, et al. (2012) Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis. World J Gastroenterol 18: 872-881.
7. Pepys MB, Druguet M, Klass HJ, Dash AC, Mirjah DD, et al. (1977) Immunological studies in inflammatory bowel disease. In: Porter R, Knight J, editors. Immunology of the gut, Ciba Foundation Symposium. Amsterdam: Elsevier, Excerpta Medica, North Holland. 283-297.
8. Saverymuttu SH, Hodgson HJ, Chadwick VS, Pepys MB, (1986) Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 27: 809-813.
9. Breda L, Nozzi M, De Sanctis S, Chiarelli F, (2010) Laboratory tests in the diagnosis and follow-up of pediatric rheumatic diseases: an update. Semin Arthritis Rheum 40: 53-72.
10. Arnold JN, Saldova R, Hamid UM, Rudd PM, (2008) Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 8: 3284-3293.
11. Shinzaki S, Iijima H, Nakagawa T, Egawa S, Nakajima S, et al. (2008) IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease. Am J Gastroenterol 103: 1173-1181.
12. Nishimura S, (2011) Toward automated glycan analysis. Adv Carbohydr Chem Biochem 65: 219-271.
13. Rachmilewitz D, (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298: 82-86.
14. Best WR, Becktel JM, Singleton JW, Kern F Jr, (1976) Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70: 439-444.
15. Langholz E, Munkholm P, Davidsen M, Binder V, (1994) Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107: 3-11.
16. Schroeder KW, Tremaine WJ, Ilstrup DM, (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317: 1625-1629.
17. Hiraoka S, Kato J, Suzuki H, Yamamoto K, (2012) Readministration of calcineurin inhibitors for ulcerative colitis. Ann Pharmacother 46: 1315-1321.
18. Azuma Y, Murata M, Matsumoto K, (2000) Alteration of sugar chains on alpha(1)-acid glycoprotein secreted following cytokine stimulation of HuH-7 cells in vitro. Clin Chim Acta 294: 93-103.
19. Phillips ML, Nudelman E, Gaeta FC, Perez M, Singhal AK, et al. (1990) ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex. Science 250: 1130-1132.
20. Thompson S, Dargan E, Griffiths ID, Kelly CA, Turner GA (1993) The glycosylation of haptoglobin in rheumatoid arthritis. Clin Chim Acta 220, 107-114.
21. Goodarzi MT, Turner GA, (1998) Reproducible and sensitive determination of charged oligosaccharides from haptoglobin by PNGase F digestion and HPAEC/PAD analysis: glycan composition varies with disease. Glycoconj J 15: 469-475.
22. Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, et al. (2007) Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 17: 1344-1356.
23. Nouso K, Amano M, Ito YM, Miyahara K, Morimoto Y, et al. (2013) Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer. J Gastroenterol [In press].
24. van Dijk W, Havenaar EC, Brinkman-van der Linden EC, (1995) Alpha 1-acid glycoprotein (orosomucoid): Pathophysiological changes in glycosylation in relation to its function. Glycoconj J 12: 227-233.
25. Fassbender K, Zimmerli W, Kissling R, Sobieska M, Aeschlimann A, et al. (1991) Glycosylation of alpha 1-acid glycoprotein in relation to duration of disease in acute and chronic infection and inflammation. Clin Chim Acta 203: 315-327.
26. Mackiewicz A, Mackiewicz K, (1995) Glycoforms of serum alpha 1-acid glycoprotein as markers of inflammation and cancer. Glycoconj J 12: 241-247.
27. Ishida H, Koyama I, Sawada T, Murakami T, Utsumi K, et al. (2000) Clinical utility of monitoring sialyl Lewis(X) (CD15S) antigen on peripheral lymphocytes for the diagnosis and treatment of rejection after renal transplantation. Transplantation 69: 59-63.
28. Axford JS, Sumar N, Alavi A, Isenberg DA, Young A, et al. (1992) Changes in normal glycosylation mechanisms in autoimmune rheumatic disease. J Clin Invest 89: 1021-1031.
29. Nakajima S, Iijima H, Shinzaki S, Egawa S, Inoue T, et al. (2011) Functional analysis of agalactosyl IgG in inflammatory bowel disease patients. Inflamm Bowel Dis 17: 927-936.
30. Bekesova S, Kosti O, Chandler KB, Wu J, Madej HL, et al. (2012) N-glycans in liver-secreted and immunoglogulin-derived protein fractions. J Proteomics 75: 2216-2224.
31. Shinzaki S, Iijima H, Fujii H, Kuroki E, Tatsunaka N, et al. (2012) Altered oligosaccharide structures reduce colitis induction in mice defective in ß-1,4-galactosyltransferase. Gastroenterology 142: 1172-1182.